Clinical Trial Update: Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants [Phase 3]

View source ↗

Summary

Phase 3 study evaluating long-acting injectable cabotegravir and rilpivirine for maintaining virologic suppression in HIV-1–infected participants who switch fro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• cabotegravir (cabotegravir)
• rilpivirine (rilpivirine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2019-10-29